Temporal Analysis of Brd4 Displacement in the Control of B Cell Survival, Proliferation, and Differentiation.

[1]  Steven L Salzberg,et al.  Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype , 2019, Nature Biotechnology.

[2]  P. Hodgkin,et al.  Regulatory T Cells Suppress Effector T Cell Proliferation by Limiting Division Destiny , 2018, Front. Immunol..

[3]  Nghi Nguyen,et al.  Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth , 2018, Nature.

[4]  Jesse J. Lipp,et al.  SLAM-seq defines direct gene-regulatory functions of the BRD4-MYC axis , 2018, Science.

[5]  Young Hwan Park,et al.  JQ1, a BET inhibitor, controls TLR4-induced IL-10 production in regulatory B cells by BRD4-NF-κB axis , 2017, BMB reports.

[6]  Erez Lieberman Aiden,et al.  Myc Regulates Chromatin Decompaction and Nuclear Architecture during B Cell Activation. , 2017, Molecular cell.

[7]  Antonio Martínez,et al.  The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling , 2017, Haematologica.

[8]  P. Grandi,et al.  Click chemistry enables preclinical evaluation of targeted epigenetic therapies , 2017, Science.

[9]  Christopher J. Ott,et al.  BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1 , 2017, Cell reports.

[10]  P. Hodgkin,et al.  A Myc-dependent division timer complements a cell-death timer to regulate T cell and B cell responses , 2016, Nature Immunology.

[11]  C. Arrowsmith,et al.  BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models. , 2016, The Journal of clinical investigation.

[12]  Andrew J. Bannister,et al.  Functional interdependence of BRD4 and DOT1L in MLL leukemia , 2016, Nature Structural &Molecular Biology.

[13]  Stefan P. Glaser,et al.  BET inhibition represses miR17-92 to drive BIM-initiated apoptosis of normal and transformed hematopoietic cells , 2016, Leukemia.

[14]  J. Mesirov,et al.  The Molecular Signatures Database Hallmark Gene Set Collection , 2015 .

[15]  Shitong Wei,et al.  Therapeutic targeting of BET protein BRD4 delays murine lupus. , 2015, International immunopharmacology.

[16]  Aaron T. L. Lun,et al.  csaw: a Bioconductor package for differential binding analysis of ChIP-seq data using sliding windows , 2015, Nucleic acids research.

[17]  B. Illi,et al.  Myc and Omomyc functionally associate with the Protein Arginine Methyltransferase 5 (PRMT5) in glioblastoma cells , 2015, Scientific Reports.

[18]  M. Mokry,et al.  Autoimmune disease-associated gene expression is reduced by BET-inhibition , 2015, Genomics data.

[19]  Łukasz M. Boryń,et al.  Transcriptional plasticity promotes primary and acquired resistance to BET inhibition , 2015, Nature.

[20]  Mark A. Dawson,et al.  BET inhibitor resistance emerges from leukaemia stem cells , 2015, Nature.

[21]  Robert A Copeland,et al.  A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models. , 2015, Nature chemical biology.

[22]  R. Johnstone,et al.  Manipulation of B-cell responses with histone deacetylase inhibitors , 2015, Nature Communications.

[23]  Yuanyuan Yang,et al.  BRAD4 plays a critical role in germinal center response by regulating Bcl-6 and NF-κB activation. , 2015, Cellular immunology.

[24]  J. H. Park,et al.  Protein arginine methyltransferase 5 is a key regulator of the MYCN oncoprotein in neuroblastoma cells , 2014, Molecular oncology.

[25]  D. Choi,et al.  PRMT5 is essential for the eIF4E-mediated 5'-cap dependent translation. , 2014, Biochemical and biophysical research communications.

[26]  Marco J. Morelli,et al.  Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis , 2014, Nature.

[27]  G. Smyth,et al.  voom: precision weights unlock linear model analysis tools for RNA-seq read counts , 2014, Genome Biology.

[28]  Charles Y. Lin,et al.  Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. , 2013, Cancer cell.

[29]  Jie H. S. Zhou,et al.  Quantal and graded stimulation of B lymphocytes as alternative strategies for regulating adaptive immune responses , 2013, Nature Communications.

[30]  Wei Shi,et al.  featureCounts: an efficient general purpose program for assigning sequence reads to genomic features , 2013, Bioinform..

[31]  Andrew Filby,et al.  Regulation of asymmetric cell division and polarity by Scribble is not required for humoral immunity , 2013, Nature Communications.

[32]  K. Ozato,et al.  BRD4 Coordinates Recruitment of Pause Release Factor P-TEFb and the Pausing Complex NELF/DSIF To Regulate Transcription Elongation of Interferon-Stimulated Genes , 2013, Molecular and Cellular Biology.

[33]  Steven L Salzberg,et al.  Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.

[34]  Jhagvaral Hasbold,et al.  Activation-Induced B Cell Fates Are Selected by Intracellular Stochastic Competition , 2012, Science.

[35]  S. Lowe,et al.  RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia , 2011, Nature.

[36]  P. Sandy,et al.  Targeting MYC dependence in cancer by inhibiting BET bromodomains , 2011, Proceedings of the National Academy of Sciences.

[37]  R. Young,et al.  BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.

[38]  Marcel Martin.  Cutadapt removes adapter sequences from high-throughput sequencing reads , 2011 .

[39]  William B. Smith,et al.  Selective inhibition of BET bromodomains , 2010, Nature.

[40]  C. Glass,et al.  Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. , 2010, Molecular cell.

[41]  Philip D. Hodgkin,et al.  A minimum of two distinct heritable factors are required to explain correlation structures in proliferating lymphocytes , 2010, Journal of The Royal Society Interface.

[42]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[43]  Clifford A. Meyer,et al.  Model-based Analysis of ChIP-Seq (MACS) , 2008, Genome Biology.

[44]  Philip D. Hodgkin,et al.  Quantitative Regulation of B Cell Division Destiny by Signal Strength , 2008, The Journal of Immunology.

[45]  John F Markham,et al.  Measuring lymphocyte proliferation, survival and differentiation using CFSE time-series data , 2007, Nature Protocols.

[46]  P. Hodgkin,et al.  A model of immune regulation as a consequence of randomized lymphocyte division and death times , 2007, Proceedings of the National Academy of Sciences.

[47]  P. Hodgkin,et al.  The proliferative response of CD4 T cells to steady-state CD8+ dendritic cells is restricted by post-activation death. , 2006, International immunology.

[48]  J. Mesirov,et al.  From the Cover: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005 .

[49]  Andreas Villunger,et al.  p53- and Drug-Induced Apoptotic Responses Mediated by BH3-Only Proteins Puma and Noxa , 2003, Science.

[50]  M. Daly,et al.  PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.

[51]  A. Strasser,et al.  Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. , 1999, Science.

[52]  P. Hodgkin,et al.  Switching to IgG3, IgG2b, and IgA is division linked and independent, revealing a stochastic framework for describing differentiation. , 1999, Journal of immunology.

[53]  D. Green,et al.  Apoptotic cell death induced by c-myc is inhibited by bcl-2 , 1992, Nature.

[54]  D. Green,et al.  Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas. , 1992, Science.

[55]  N. Copeland,et al.  Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis , 1992, Nature.

[56]  A. W. Harris,et al.  The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells , 1988, The Journal of experimental medicine.

[57]  R. Palmiter,et al.  The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice , 1985, Nature.

[58]  F. Burnet.  A modification of jerne's theory of antibody production using the concept of clonal selection , 1976, CA: a cancer journal for clinicians.

[59]  S. Heinzel,et al.  Epigenetic targeting of Notch1-driven transcription using the HDACi panobinostat is a potential therapy against T-cell acute lymphoblastic leukemia , 2018, Leukemia.

[60]  A. Stathis,et al.  BET Proteins as Targets for Anticancer Treatment. , 2018, Cancer discovery.

[61]  S. Tangye,et al.  Evidence from the generation of immunoglobulin G–secreting cells that stochastic mechanisms regulate lymphocyte differentiation , 2004, Nature Immunology.